Literature DB >> 33782306

PET Imaging of Meningioma Using the Novel SSTR-Targeting Peptide 18F-SiTATE.

Marcus Unterrainer, Simon Lindner1, Leonie Beyer1, Franz J Gildehaus1, Andrei Todica1, Lena M Mittlmeier1, Klaus Jurkschat2, Carmen Wängler3, Bjoern Wängler4, Ralf Schirrmacher5, Jörg C Tonn6, Nathalie L Albert1, Peter Bartenstein1, Harun Ilhan1.   

Abstract

ABSTRACT: PET using 68Ga-labeled somatostatin receptor (SSTR) ligands adds significant information in meningioma patients. 18F-SiTATE is a novel, 18F-labeled SSTR-targeting peptide with remarkable imaging properties. Here, we present a 72-year-old woman with falx meningioma and transosseous extension. 18F-SiTATE PET/CT was performed 12 months after the previous 68Ga-DOTATOC PET/CT with comparable quantitative uptake and very good spatial resolution. So far, the widespread use of SSTR ligands for NET and meningioma imaging is hampered by cost-intensive 68Ge/68Ga generators, low activity amounts, lower spatial resolution, and short half-life. 18F-SiTATE might foster widespread use of SSTR ligands, overcoming the shortcomings of 68Ga-labeled ligands.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33782306     DOI: 10.1097/RLU.0000000000003607

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  1 in total

1.  Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [18F]SiTATE PET.

Authors:  Carmen Wängler; Leonie Beyer; Peter Bartenstein; Björn Wängler; Ralf Schirrmacher; Simon Lindner
Journal:  EJNMMI Radiopharm Chem       Date:  2022-09-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.